Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pasritamig plus docetaxel versus docetaxel in metastatic castration-resistant prostate cancer
ISRCTN12271587Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2026
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
01
Overview
Phase 3, randomised, open-label trial of pasritamig, docetaxel and prednisolone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoint: Radiographic progression-free survival. Started Jan 2026; status: recruiting.
02
Drugs
pasritamigdocetaxelprednisolone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on ISRCTN12271587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN12271587.